Board of Directors
Chief Development Officer
Dipen Desai, Ph.D. joined Azurity in January 2023 as Chief Development officer where he is responsible for all R&D functions, including new product development and approval. Dipen has more than 15 years of experience leading the development of drug delivery technologies and drug products for new drug molecules, 505b(2) and complex generics products. He has held various scientific positions including Vice President, Complex Product Research at Amneal pharmaceuticals; Vice President of Formulation and Analytical R&D at Kashiv and Hoffmann-La Roche. Dipen and his teams have been instrumental in developing platform technologies for several products.
Dipen has been named as an inventor for more than 40 approved patents and applications. He also has published multiple original research articles and book chapters in the field of formulation development and drug delivery technologies. Dipen received his Masters and Ph.D. in pharmaceutical sciences from the University of Rhode Island, and holds an MBA from NYU Stern School of Business.